Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 7. november 2023 | | | |
|--|--|--|--|
| Your name: Josefine Amalie Loft | | | |
| Manuscript title: Maribavir til behandling af cytomegalovirus-infektion hos en levertransplanteret patient | | | |
| Manuscript number (if known): UFL-11-23-0687 | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|--|---|
| 1 | All support for the present | | |
| | | ⊠ None | |
| | manuscript (e.g., funding, provision of study | | |
| | | | |
| | materials, medical writing, | | |
| | article processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | | | |
| | item. | | |

Click TAB in last row to add extra rows

| 2 | Grants or contracts from | ⊠ None | |
|---|------------------------------|--------|--|
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | 🖾 None | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|--|--------|
| | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | ⊠ None |
| 7 | Support for attending meetings and/or travel | ⊠ None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None |
| 11 | Stock or stock options | ⊠ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None |
| 13 | Other financial or non- financial interests | ⊠ None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 14. november 2023 | | | |
|--|--|--|--|
| Your name: Paul Suno Krohn | | | |
| Manuscript title: Maribavir til behandling af cytomegalovirus-infektion hos en levertransplanteret patient | | | |
| Manuscript number (if known): | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---------------------------------|--|---|
| 1 | All support for the present | None | |
| ' | manuscript (e.g., funding, | | |
| | provision of study | | |
| | | | |
| | materials, medical writing, | | |
| | article processing charges, | | |
| | etc.) | | |
| | | | |
| | No time limit for this | | |
| | item. | | |

Click TAB in last row to add extra rows

| 2 | 2 Grants or contracts from | ⊠ None | |
|---|------------------------------|--------|--|
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | 🖾 None | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None | 1 |
|----|--|--|-------------------------|
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None Takeda CMV-lecture | payment were made to me |
| 6 | Payment for expert testimony | None Takeda CMV Advisory board | payment were made to me |
| 7 | Support for attending meetings and/or travel | ⊠ None | |
| 8 | Patents planned, issued or pending | ⊠ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None | |
| 11 | Stock or stock options | ⊠ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None | |
| 13 | Other financial or non- financial interests | ⊠ None | |

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 17. november 2023 | | | | |
|--|--|--|--|--|
| Your name: Stephanie Bjerrum | | | | |
| Manuscript title: Maribavir til behandling af cytomegalovirus-infektion hos en levertransplanteret patient | | | | |
| Manuscript number (if known): | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None | |
| | No time limit for this item. | | |

Click TAB in last row to add extra rows

| 2 | Grants or contracts from | ⊠ None | |
|---|------------------------------|--------|--|
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | ⊠ None | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|--|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | ☑ None |
| 7 | Support for attending meetings and/or travel | ⊠ None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☑ None |
| 11 | Stock or stock options | ⊠ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑ None |
| 13 | Other financial or non- financial interests | ⊠ None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 15. november 2023 | | |
|---|--|--|
| Your name: Kristian Schønning | | |
| Manuscript title: Maribavir til behandling af cytomegolovirus-infektion hos en levertransplanteret patient. | | |
| Manuscript number (if known): UFL-11-23-0687 | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---------------------------------|--|---|
| 1 | All support for the present | None | |
| ' | manuscript (e.g., funding, | | |
| | | | |
| | provision of study | | |
| | materials, medical writing, | | |
| | article processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | No time limit for this | | |
| | item. | | |

Click TAB in last row to add extra rows

| 2 | Grants or contracts from | ⊠ None | |
|---|------------------------------|--------|--|
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | 🖾 None | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|--|--|
| | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☑ None Image: Second |
| 6 | Payment for expert testimony | ⊠ None |
| 7 | Support for attending meetings and/or travel | ⊠ None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None |
| 11 | Stock or stock options | ⊠ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None |
| 13 | Other financial or non- financial interests | ⊠ None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 14. november 2023 | | | |
|--|-----------------------------|--|--|
| Your name: Peter | Your name: Peter Theut Riis | | |
| Manuscript title: Maribavir til behandling af cytomegalovirus-infektion hos en levertransplanteret patient | | | |
| Manuscript number (if known): UFL-11-23-0687 | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---------------------------------|--|---|
| 1 | All support for the present | | |
| | | ⊠ None | |
| | manuscript (e.g., funding, | | |
| | provision of study | | |
| | materials, medical writing, | | |
| | article processing charges, | | |
| | etc.) | | |
| | No time the it for this | | |
| | No time limit for this | | |
| | item. | | |

Click TAB in last row to add extra rows

| 2 | Grants or contracts from | ⊠ None | |
|---|------------------------------|--------|--|
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | ⊠ None | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|--|--------|
| | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | ⊠ None |
| 7 | Support for attending meetings and/or travel | ⊠ None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None |
| 11 | Stock or stock options | ⊠ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None |
| 13 | Other financial or non- financial interests | ⊠ None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 21. november 2023 | | | |
|--|------------------------------------|--|--|
| Your name: Christ | Your name: Christian Ross Pedersen | | |
| Manuscript title: Maribavir til behandling af cytomegalovirus-infektion hos en levertransplanteret patient | | | |
| Manuscript number (if known): UFL-11-23-0687 | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|--|---|
| | • | | |
| 1 | All support for the present | 🛛 None | |
| | manuscript (e.g., funding, provision of study | | |
| | | | |
| | materials, medical writing, | | |
| | article processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | No time limit for this | | |
| | item. | | |

Click TAB in last row to add extra rows

| 2 | Grants or contracts from | ⊠ None | |
|---|------------------------------|--------|--|
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | 🖾 None | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|--|--------|
| | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | ⊠ None |
| 7 | Support for attending meetings and/or travel | ⊠ None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None |
| 11 | Stock or stock options | ⊠ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None |
| 13 | Other financial or non- financial interests | ⊠ None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 21. november 2023 | | | |
|--|--|--|--|
| Your name: Nicolai Aagaard Schultz | | | |
| Manuscript title: Maribavir til behandling af cytomegalovirus-infektion hos en levertransplanteret patient | | | |
| Manuscript number (if known): UFL-11-23-0687 | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|--|---|
| 1 | All support for the present | | |
| | | ⊠ None | |
| | manuscript (e.g., funding, provision of study | | |
| | | | |
| | materials, medical writing, | | |
| | article processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | | | |
| | item. | | |

Click TAB in last row to add extra rows

| 2 | Grants or contracts from | ⊠ None | | |
|---|---|--------|--|--|
| | any entity (if not indicated in item #1 above). | | | |
| | | | | |
| | | | | |
| 3 | Royalties or licenses | ⊠ None | | |
| | | | | |
| | | | | |

| 4 | Consulting fees | ⊠ None |
|----|--|--|
| | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☑ None Image: Second |
| 6 | Payment for expert testimony | ⊠ None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None |
| 11 | Stock or stock options | ⊠ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None |
| 13 | Other financial or non- financial interests | ⊠ None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

| Date: 21. november 2023 | | | |
|--|--|--|--|
| Your name: Susanne Dam Poulsen | | | |
| Manuscript title: Maribavir til behandling af cytomegalovirus-infektion hos en levertransplanteret patient | | | |
| Manuscript number (if known): UFL-11-23-0687 | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Tim | e frame: Since the initial plar | Name all entities with whom you have this relationship or indicate none (add rows as needed) nning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Novo Nordic Foundation | Research grant |
| | No time limit for this item. | | |

Click TAB in last row to add extra rows

| 2 | Grants or contracts from | □ None | |
|---|------------------------------|-----------------------|----------------|
| | any entity (if not indicated | Kirsten og Freddy | Research grant |
| | in item #1 above). | Johansens Fond | |
| | | Læge Sofus Carl Emil | Research grant |
| | | Arvid Nilssons Fond | Research grant |
| | | Københavns Medicinske | Research grant |
| | | Selskab | |
| | | Augustinus | Research grant |
| | | NNF Tandem | Research grant |

| | | EU HORIZONT | Research grant |
|---|--------------------------------|-------------------------|----------------|
| | | Regionernes Medicin- og | Research grant |
| | | Behandlingspulje | |
| | | Rigshospitalets | Research grant |
| | | Forskningsudvalg | |
| | | Gilead Fellowship | Research grant |
| | | Svend Andersen Fonden | Research grant |
| 3 | 3 Royalties or licenses X None | | |
| Ũ | | | |
| | | | |
| | | | |

| 4 | Consulting fees | 🖾 None | |
|----|--|---|------------------------|
| | | | |
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | Gilead MSD | Honoraria Honoraria |
| | | | |
| 6 | Payment for expert testimony | ⊠ None | |
| 7 | Support for attending meetings and/or travel | ⊠ None | |
| 8 | Patents planned, issued or pending | ☑ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | □ None Has served on advisory boards for Gilead, MSD, Takeda, and GSK. | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None | |
| 11 | Stock or stock options | ⊠ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None | |
| 13 | Other financial or non- financial interests | ⊠ None | |

Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal